Recombinant Mouse Zinc transporter 7 (Slc30a7)

What is the basic molecular structure of mouse Slc30a7 and how does it compare to human ZnT7?

Mouse Slc30a7, like its human ortholog, is a member of the SLC30 family of zinc transporters that contains six transmembrane domains and a distinctive histidine-rich loop positioned between transmembrane domains IV and V. The protein exists as a dimer, with tight interactions in both the cytosolic and transmembrane domains. Each protomer contains a single zinc-binding site in its transmembrane domain that serves as a critical component of the zinc transport pathway. The mouse Slc30a7 protein is predicted to be 387 amino acids in length, sharing high sequence conservation with human ZnT7, particularly in the transmembrane regions and the functional histidine-rich loop .

For experimental characterization, researchers should consider using techniques such as Western blotting with specific antibodies targeting conserved epitopes. Previous studies successfully employed an affinity-purified antibody raised against amino acids 299-315 of mouse ZnT7, which detected proteins with apparent molecular masses of 85, 43, and 65 kDa in small intestine and lung tissues .

How can I confirm successful expression of recombinant mouse Slc30a7 in cellular systems?

When expressing recombinant mouse Slc30a7 in cellular systems, verification protocols should include:

• Immunofluorescence microscopy to confirm Golgi localization, which is characteristic of Slc30a7. The protein should co-localize with Golgi markers and appear in cytoplasmic vesicles .

• Functional zinc accumulation assays using zinc-sensitive fluorescent probes. When exposing Slc30a7-expressing cells (such as transfected CHO cells) to zinc, researchers should observe zinc accumulation in the Golgi apparatus, confirming the functionality of the recombinant protein .

• Western blot analysis with anti-Slc30a7 antibodies, which should detect the protein at expected molecular weights, potentially with post-translational modifications that may cause variations in apparent molecular mass.

These verification steps are essential before proceeding with further functional or structural analyses to ensure the recombinant protein behaves similarly to the native form.

What is the normal expression pattern of Slc30a7 in mouse tissues and how can this inform recombinant protein studies?

Mouse Slc30a7 demonstrates widespread transcription across various tissues, with particularly abundant expression in the liver and small intestine. Moderate expression levels are observed in the kidney, spleen, brain, and lung . This differential expression pattern suggests tissue-specific functions that should be considered when designing recombinant protein experiments.

For accurate recombinant protein studies, researchers should:

• Consider the native expression levels when determining physiologically relevant concentrations for functional assays

• Include liver and intestinal cell lines in expression studies when evaluating functionality

• Design tissue-specific promoters for targeted expression in transgenic models

• Evaluate expression using tissue panels via RT-qPCR and compare with established baseline measurements

Understanding the natural distribution pattern helps contextualize results from heterologous expression systems and guides the selection of appropriate cell types for recombinant expression.

[Advanced] What developmental expression patterns does Slc30a7 exhibit and how can these be recapitulated in experimental models?

In developmental contexts, particularly in zebrafish models, Slc30a7 expression has been documented in several structures including the blastoderm, notochord, prechordal plate, pronephric duct, and yolk . This spatiotemporal expression pattern suggests important developmental roles that may be conserved in mammals.

To recapitulate these developmental patterns in experimental models:

• Establish time-course experiments with inducible expression systems to mimic developmental timing

• Use tissue-specific promoters for targeted expression in developmental studies

• Create reporter fusion constructs to track expression in real-time during development

• Employ CRISPR/Cas9-mediated knock-in strategies to tag endogenous Slc30a7 for accurate developmental tracking

These approaches allow researchers to study how recombinant Slc30a7 functions in contexts that mirror its natural developmental expression, providing insights into both normal physiology and potential developmental disorders associated with Slc30a7 dysfunction.

What is the current understanding of the Slc30a7 transport mechanism based on structural studies?

Recent high-resolution cryo-EM structures (2.2-3.1 Å) of human ZnT7 in both zinc-bound and unbound forms have revealed critical insights into the transport mechanism that likely apply to mouse Slc30a7 due to their high conservation . The transport mechanism involves:

• Transmembrane helix rearrangement to create a negatively charged cytosolic cavity that facilitates Zn²⁺ entry in the inward-facing conformation

• Widening of the luminal cavity to enable Zn²⁺ release in the outward-facing conformation

• A critical role for the histidine-rich loop, which binds two Zn²⁺ ions and appears to facilitate their recruitment to the transmembrane metal transport pathway

• Transient engagement of His164 within the histidine-loop in Zn²⁺ coordination at the transmembrane Zn²⁺-binding site, followed by replacement with His240, part of a zinc-binding HDHD motif in the transmembrane domain

To experimentally probe this mechanism with recombinant protein, researchers should consider site-directed mutagenesis of key histidine residues, particularly targeting His164 and components of the HDHD motif, followed by functional zinc transport assays.

[Advanced] How can I design zinc transport assays to evaluate the functionality of mutant Slc30a7 constructs?

To assess the functionality of recombinant wild-type or mutant Slc30a7 proteins, researchers should implement the following methodological approaches:

• Zinc accumulation visualization: Express recombinant Slc30a7 in appropriate cell lines (e.g., CHO cells), expose to zinc, and measure Golgi accumulation using zinc-specific fluorescent probes like FluoZin-3 or Zinpyr-1, with confocal microscopy for subcellular localization .

• Radioisotope transport assays: Utilize ⁶⁵Zn to directly measure transport kinetics across membranes in cells expressing recombinant Slc30a7. This approach can quantify rates of transport and compare efficiencies between wild-type and mutant constructs.

• pH-dependent transport measurement: Since Slc30a7 functions as a Zn²⁺/H⁺ antiporter, measure pH changes concurrent with zinc transport using pH-sensitive fluorescent proteins targeted to the Golgi lumen.

• Liposome reconstitution system: Purify recombinant Slc30a7 and incorporate into liposomes for controlled assessment of transport properties in a defined membrane environment, eliminating cellular confounding factors.

For mutation studies, prioritize the following residues based on structural insights:

• Histidine residues in the HDHD motif of the transmembrane domain

• His164 in the histidine-rich loop

• Key residues that form the negatively charged cytosolic cavity

• Residues at the dimer interface that may affect protein stability and function

A systematic analysis comparing transport rates, zinc binding affinities, and pH dependence between wild-type and mutant constructs will provide mechanistic insights into the functional domains of Slc30a7.

What are the key considerations when preparing recombinant mouse Slc30a7 for structural studies?

Based on successful structural studies of human ZnT7 , researchers working with recombinant mouse Slc30a7 should consider the following methodological approach:

• Expression optimization: Use mammalian expression systems rather than bacterial systems to ensure proper folding and post-translational modifications. HEK293 cells have proven successful for human ZnT7 expression and would likely work for mouse Slc30a7.

• Purification strategy:

  • Employ affinity tags that can be removed post-purification

  • Include appropriate detergents for membrane protein extraction (e.g., DDM, LMNG)

  • Consider lipid nanodisc reconstitution to maintain native-like membrane environment

  • Implement size-exclusion chromatography to isolate dimeric populations

• Stability considerations:

  • Test multiple buffer compositions with varying pH values (typically pH 7.0-8.0)

  • Include zinc in purification buffers to stabilize the protein

  • Screen detergent:lipid ratios to optimize stability

  • Evaluate protein stability using thermal shift assays

• Sample preparation for structural biology:

  • For cryo-EM: optimize protein concentration (typically 3-5 mg/ml), grid type, and vitrification conditions

  • For crystallography: screen various lipids and detergents for crystal formation

  • Consider both zinc-bound and zinc-free states to capture different conformations

Following these guidelines will increase the likelihood of obtaining stable, functional recombinant mouse Slc30a7 suitable for high-resolution structural studies.

[Advanced] How can I determine the structural basis for zinc selectivity in Slc30a7 compared to other divalent metal transporters?

To elucidate the structural determinants of zinc selectivity in recombinant mouse Slc30a7:

• Comparative metal binding studies:

  • Perform isothermal titration calorimetry (ITC) with various divalent metals (Zn²⁺, Cd²⁺, Co²⁺, Ni²⁺, Cu²⁺)

  • Measure binding affinities and thermodynamic parameters for each metal

  • Create a selectivity profile based on relative binding affinities

• Metal competition assays:

  • Use fluorescence-based zinc sensors in competition assays with other metals

  • Determine IC₅₀ values for displacement of zinc by competing metals

  • Quantify relative selectivity ratios for physiologically relevant metals

• Structural approaches to metal coordination:

  • Implement X-ray absorption spectroscopy (XAS) to determine coordination geometry of bound zinc

  • Perform anomalous X-ray diffraction at the zinc edge to precisely locate zinc binding sites

  • Use computational modeling to simulate metal binding energetics at identified sites

• Comparative mutagenesis of metal-binding sites:

  • Based on the zinc-binding HDHD motif and other coordinating residues identified in human ZnT7

  • Create systematic mutations altering the coordination chemistry (e.g., His→Cys, Asp→Glu)

  • Test mutants for altered metal selectivity profiles

  • Correlate structural changes with functional outcomes

This comprehensive approach will provide insights into the molecular basis of zinc selectivity in Slc30a7, which can inform both basic understanding of zinc transport mechanisms and potential therapeutic interventions targeting zinc homeostasis.

What is the evidence linking Slc30a7 variants to human pathologies and how can mouse models inform these associations?

Recent research has implicated de novo heterozygous variants in SLC30A7 as potential causes of Joubert syndrome (JS), a well-established ciliopathy characterized by the distinctive molar tooth sign on brain MRI, ataxia, and neurodevelopmental features . Two specific variants have been identified:

• A de novo heterozygous missense variant (NM_133496.5: c.407T>C, p.Val136Ala)

• A de novo deletion-insertion variant (c.490_491delinsAG, p.His164Ser)

Both variants affect highly conserved residues and meet criteria for being likely pathogenic . Notably, the His164 residue implicated in the second variant has been identified as functionally important for zinc binding and transport in structural studies .

To develop mouse models that inform these human disease associations:

• Generate knock-in mice carrying the equivalent mouse mutations using CRISPR/Cas9 genome editing

• Create conditional and tissue-specific Slc30a7 knockout models to assess developmental consequences

• Examine ciliary structure and function in these models, given the connection to ciliopathies

• Assess neurodevelopmental outcomes through behavioral testing and brain imaging

Researchers should also note that SLC30A7 appears to interact with TCTN3, another protein associated with Joubert syndrome, suggesting potential involvement in primary cilia and Sonic Hedgehog signaling pathways .

[Advanced] How can recombinant Slc30a7 be used to investigate the molecular basis of ciliopathy-associated variants?

To investigate the molecular mechanisms by which Slc30a7 variants may contribute to ciliopathies:

• In vitro biochemical characterization:

  • Generate recombinant wild-type and mutant (p.Val136Ala and p.His164Ser) Slc30a7 proteins

  • Compare zinc transport activities using liposome-based transport assays

  • Assess protein stability and folding using thermal shift assays and limited proteolysis

  • Evaluate changes in dimerization using size-exclusion chromatography coupled with multi-angle light scattering

• Structural analysis of disease variants:

  • Obtain structures of mutant proteins using cryo-EM or X-ray crystallography

  • Compare conformational changes between wild-type and mutant proteins

  • Focus on potential alterations in the zinc binding pocket or conformational flexibility

• Protein-protein interaction studies:

  • Investigate interactions with known ciliary proteins, particularly TCTN3

  • Perform co-immunoprecipitation and proximity labeling assays

  • Use fluorescence resonance energy transfer (FRET) to detect direct interactions in live cells

  • Compare interaction profiles between wild-type and mutant proteins

• Cellular phenotype characterization:

  • Express wild-type and mutant proteins in ciliated cell models

  • Assess effects on cilia formation, length, and function

  • Measure Sonic Hedgehog pathway activity using reporter assays

  • Evaluate zinc homeostasis in the ciliary compartment using targeted sensors

• Developmental signaling pathway analysis:

  • Analyze alterations in developmental signaling pathways known to be affected in ciliopathies

  • Focus on Sonic Hedgehog, Wnt, and Notch signaling outcomes

  • Measure pathway activity in cells expressing wild-type versus mutant proteins

This multifaceted approach will provide insights into how specific Slc30a7 variants disrupt normal protein function and contribute to ciliopathy phenotypes, potentially identifying targets for therapeutic intervention.

What are the known interaction partners of Slc30a7 and how can these interactions be validated experimentally?

Research indicates that Slc30a7 participates in specific protein-protein interactions that contribute to its biological functions. Notably, proteomic studies support an interaction between SLC30A7 and TCTN3, a protein associated with Joubert syndrome . Additionally, ZnT7 homodimers play critical roles in the activation of zinc ectoenzymes such as alkaline phosphatases .

To experimentally validate and characterize these interactions using recombinant mouse Slc30a7:

• Co-immunoprecipitation assays:

  • Express epitope-tagged recombinant Slc30a7 in appropriate cell lines

  • Immunoprecipitate Slc30a7 and blot for potential interacting partners

  • Perform reciprocal co-IP with suspected partners (e.g., TCTN3)

  • Include appropriate controls for membrane protein interactions

• Proximity-based labeling approaches:

  • Generate Slc30a7 fusion constructs with BioID or APEX2

  • Express in relevant cell types and activate labeling

  • Identify proximal proteins using mass spectrometry

  • Validate top candidates with orthogonal methods

• Fluorescence-based interaction assays:

  • Use bimolecular fluorescence complementation (BiFC) to visualize interactions in live cells

  • Employ FRET or FLIM-FRET to detect direct protein-protein associations

  • Correlate interaction signals with subcellular localization

• Functional validation of interactions:

  • Disrupt specific interactions through targeted mutations

  • Assess consequences on zinc transport activity

  • Evaluate effects on partner protein localization and function

  • Measure activity of zinc-dependent enzymes following interaction disruption

These approaches will provide comprehensive insights into the Slc30a7 interactome and its functional significance in various cellular contexts.

[Advanced] How does Slc30a7 contribute to the activation of zinc ectoenzymes and what experimental designs can probe this function?

ZnT7 homodimers have been implicated in the activation of zinc ectoenzymes, including alkaline phosphatases . To investigate this function using recombinant mouse Slc30a7:

Table 1: Experimental Approach to Study Slc30a7's Role in Zinc Ectoenzyme Activation

For zinc ectoenzyme activation studies, researchers should focus on:

• Early secretory pathway dynamics:

  • Track zinc-dependent enzyme folding and maturation in the presence or absence of functional Slc30a7

  • Use pulse-chase experiments to measure protein maturation rates

  • Employ glycosylation analysis to assess proper protein processing

• Zinc delivery mechanisms:

  • Determine whether direct protein-protein interactions are required for zinc transfer

  • Investigate whether zinc is delivered to the enzyme active site or to structural zinc-binding sites

  • Assess whether Slc30a7 influences enzyme dimerization or oligomerization

• Quantitative zinc requirements:

  • Establish dose-response relationships between zinc availability and enzyme activation

  • Determine the stoichiometry of zinc binding in activated enzymes

  • Measure zinc binding affinity in nascent versus mature enzyme forms

• Tissue-specific requirements:

  • Compare Slc30a7-dependent enzyme activation across tissues with differential expression

  • Correlate enzyme activity with Slc30a7 expression levels in various cell types

  • Identify tissue-specific cofactors that may modulate this process

These experimental approaches will provide mechanistic insights into how Slc30a7-mediated zinc transport contributes to the essential process of zinc ectoenzyme activation, with implications for both basic biology and potential therapeutic interventions targeting zinc-dependent processes.